Valence 로고
인기
로그인
Loading data for KNSA — first visit, this takes a few seconds.

관심목록에 추가

Kiniksa Pharmaceuticals I...

NasdaqGS: KNSA · 실시간 가격 · USD
80.20
+0.82 (1.03%)
종가 기준: Aug 27, 2026, 8:00 PM
79.80
+0.00%
애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

Kiniksa Pharmaceuticals International(KNSA) 주가, 분석 및 데이터

1.03%

데이터 없음

매수호가57.45
시가총액6.23B
매출 (ttm)840.85M
순이익 (ttm)80.66M
0.09
0.99
80.61
49.34
P/B (ttm)9.51
P/S (ttm)7.30
실적 발표일Oct 27, 2026
매도호가102.19
거래량402,049
평균 거래량 (20일)749,639
시가79.36
전일 종가79.38
일중 범위79.22 - 80.86
52주 범위32.89 - 82.94
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

KNSA 소개

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobul...

[더 보기]
산업 Drug Manufacturers - Specialty & Generic
섹터 Healthcare
IPO 일자 May 25, 2018
직원 수 366
상장 거래소 NasdaqGS
티커 KNSA
웹사이트 https://www.kiniksa.com
전체 기업 정보

재무 실적

2025년 Kiniksa Pharmaceuticals International의 매출은 677.56M로, 전년 423.24M 대비 60.09% 증가했습니다. 순이익은 59.01M로, -236.61% 감소했습니다.

재무제표

어닝 서프라이즈

Kiniksa Pharmaceuticals International가 Jul 28, 2026에 분기 실적을 발표했습니다:
  • 매출 $243.6M 예상치 하회 $0, 및 55.36% 전년 대비 성장.
  • EPS 0.3 예상치 상회 0.02, 및 30.43% 전년 대비 성장.

다음 실적 발표

Kiniksa Pharmaceuticals International의 실적 발표 예정일은 Oct 27, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드
news image

3일 전 · Investor's Business Daily

TGTX Stock Outperforms 95% of Stocks. Here's Why.

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

news image

6일 전 · Investor's Business Daily

Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan

Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan.

news image

6일 전 · Investor's Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

news image

1주 전 · MarketBeat

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-o...

news image

3주 전 · Zacks

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.

2 페이지 중 1